32 VOLUME 20 NUMBER 2 • NOVEMBER 2023 REVIEW SA JOURNAL OF DIABETES & VASCULAR DISEASE Clin Endocrinol Metab 2015; 100(8): 2849–2852. 23. Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Molec Sci 2023; 24(7): 6039. 24. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 2020; 16(11): 642–653. 25. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53(Suppl_3): S190–S196. 26. Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Safety 2018; 17(4): 387–405. 27. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. J Am Med Assoc Cardiol 2016; 1(2): 126–135. 28. Scirica BM, Mosenzon O, Bhatt DL, Jacob AU, Steg PG, McGuire DK, et al. Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial. J Am Med Assoc Cardiol 2018; 3(2): 155–163. 29. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011; 33(11): 1609–1629. 30. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, Webber T, et al. Glucosedependent insulinotropic polypeptide is expressed in pancreatic islet α-cells and promotes insulin secretion. Gastroenterology 2010; 138(5): 1966–1975. 31. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, crossover study. Curr Med Res Opin 2008; 24(10): 2943–2952. 32. Basso N, Capoccia D, Rizzello M, Abbatini F, Mariani P, Maglio C, et al. Firstphase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis. Surg Endoscopy 2011; 25: 3540–3550. 33. Shaefer Jr CF, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med 2015; 127(8): 818–826. 34. Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol 2020; 11: 178. 35. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7(10): 776–785. 36. Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obesity Metab 2018; 20(4): 889–897. 37. Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obesity Metab 2020; 22(8): 1263–1277. 38. Honigberg MC, Chang L-S, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. J Am Med Assoc Cardiol 2020; 5(10): 1182– 1190. 39. Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61–69. 40. Mancini GJ, O’Meara E, Zieroth S, Bernier M, Cheng AY, Cherney DZ, et al. 2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Can J Cardiol 2022; 38(8): 1153–1167. 41. Shami D, Sousou JM, Batarseh E, Alazrai L, Batarseh E, Alazrai LI. The roles of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors in decreasing the occurrence of adverse cardiorenal events in patients with type 2 diabetes. Cureus 2023; 15(1). 42. Bertoccini L, Baroni MG. GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection. In: Islam MS (ed). Diabetes: From Research to Clinical Practice: Volume 4. Cham: Springer Int, 2021: 193–212. 43. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and antiatherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4inhibitors. Expert Opin Invest Drugs 2009; 18(10): 1495–1503. 44. American Diabetes Association. Classification and diagnosis of diabetes: practices.3 There is an urgent need for clinicians to adopt the latest evidence and modify their approach from traditional diabetes medications to newer therapies that have been shown to reduce cardiovascular risk. References 1. World Health Organization, Canada. Preventing chronic diseases: a vital investment: World Health Organization, 2005. 2. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep 2019; 21: 1–8. 3. Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, et al. Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales. Front Pharmacol 2022; 12: 4119. 4. Corrao S, Pinelli K, Vacca M, Raspanti M, Argano C. Type 2 diabetes mellitus and COVID-19: a narrative review. Front Endocrinol 2021; 12: 609470. 5. Fei Y, Tsoi M-F, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol 2019; 18(1): 1–13. 6. Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, et al. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Primary Care Diabetes 2019; 13(3): 204–211. 7. Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377–385. 8. Idris I, Donnelly R. Sodium-glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obesity Metab 2009; 11(2): 79–88. 9. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design Develop Ther 2014: 1380. 10. Donnan K, Segar L. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 2019; 846: 23–29. 11. Yu J, Zhou Z, Mahaffey KW, Matthews DR, Neuen BL, Heerspink HJ, et al. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. Int J Cardiol 2021; 324: 165–172. 12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE) – TIMI 58 Trial. Am Heart J 2018; 200: 83–89. 13. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TD, Elvan A, et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF). Eur J Heart Fail 2020; 22(4): 713–722. 14. Boorsma EM, Beusekamp JC, Ter Maaten JM, Figarska SM, Danser AJ, van Veldhuisen DJ, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail 2021; 23(1): 68–78. 15. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a metaanalysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396(10254): 819–829. 16. Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other largescale trials nearing completion. Cardiovasc Diabetol 2019; 18: 1–4. 17. Rhee JJ, Jardine MJ, Chertow GM, Mahaffey KW. Dedicated kidney disease‐ focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐ KIDNEY. Diabetes Obesity Metab 2020; 22: 46–54. 18. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Med 2022; 28(9): 1956– 1964. 19. Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia 2019; 62: 926–938. 20. Fitchett D. A safety update on sodium glucose co‐transporter 2 inhibitors. Diabetes Obesity Metab 2019; 21: 34–42. 21. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013; 125(3): 33–46. 22. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J
RkJQdWJsaXNoZXIy NDIzNzc=